BackDamora Therapeutics Overview

Damora Therapeutics Total Liabilities

Track Damora Therapeutics's total liabilities ($28M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$27.58M
↑ 576.07% YoYΔ $23.50M vs prior year quarter

Peer trimmed avg / median

Loading

Damora Therapeutics Total Liabilities History

Loading

Damora Therapeutics vs. peers: Total Liabilities Comparison

Loading

Damora Therapeutics Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Damora Therapeutics (DMRA) FAQ

Damora Therapeutics (DMRA) currently reports a total liabilities of $28M as of June 2026. That compares with $4.1M in the prior-year period — up 576.1% year over year. Use the charts on this page to explore Damora Therapeutics's total liabilities history and peer comparisons.

Damora Therapeutics's total liabilities increased from $4.1M to $28M — a 576.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Damora Therapeutics reported $28M in total liabilities as of June 2026. That compares with $4.1M in the prior-year period — up 576.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $28M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Damora Therapeutics, and consider following DMRA for alerts when major investors trade the stock.

Damora Therapeutics is classified in the Healthcare sector. On total liabilities, it currently shows $28M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DMRA with unrelated industries.